May 3, 2025 — Rather quietly this week, Eli Lilly and Company announced that it had withdrawn an application to FDA for an indication to use tirzepatide (Zepbound) in treating heart failure – specifically for HFpEF. This news came up in a briefing for investors, with Lilly’s Chief Scientific Officer, Dan Skovronsky, saying: “Following discussions with the FDA, we’ve […]
March 20, 2025 — It’s unmistakable. A quick look at the upcoming meeting of the American College of Cardiology in Chicago tells us that obesity care has a growing role in cardiology. The meeting starts March 29 and a total of 27 educational sessions will focus on obesity. Three late breaking publications – two for semaglutide and one for […]
January 1, 2025 — Thankfully, 2024 is behind us now and we have a blank slate for a whole new year ahead of us. But what can we expect? Well, proverbial (probably Danish) wisdom tells us “prediction is difficult, especially if it’s about the future.” Nonetheless, here are our top five predictions about what we will see in 2025 […]
November 17, 2024 — By 38%, Tirzepatide cuts the risk of bad outcomes in persons with obesity and an increasingly common form of heart failure that obesity causes. The diagnosis is heart failure with preserved ejection fraction or HFpEF. The measure of bad outcomes it prevents was a composite worsening heart failure or death from cardiovascular disease. Worsening heart […]
August 24, 2024 — Novo Nordisk is creeping up on an indication for semaglutide in people with obesity and heart failure. Today in Lancet, we have another piece of the puzzle to suggest this drug might help. In a prespecified analysis from the SELECT study, researchers found that semaglutide reduced heart attacks, strokes, deaths, and problems with heart failure […]
August 3, 2024 — One more chapter opened this week in the ongoing story of diseases that improve when healthcare providers effectively treat obesity. Lilly announced topline results from a study showing that tirzepatide cuts the rate of adverse heart failure outcomes in persons with obesity and heart failure by 38% when compared to placebo. The specific form of […]
April 8, 2024 — Obesity research never rests, it seems. Over the weekend, at the American College of Cardiology annual meeting and in the New England Journal of Medicine, we got a third confirmation of the benefit that semaglutide delivers to patients with obesity and heart failure. Specifically, this is about heart failure with preserved ejection fraction – HFpEF. […]
August 28, 2023 — On Friday, NEJM published impressive results in an RCT of semaglutide for treating patients who have obesity and heart failure with preserved ejection fraction (HFpEF). The treatment enabled these people to function better, feel better, and suffer half as many serious adverse events. These are important benefits for people with a very difficult condition. But […]
August 26, 2023 — Scientists who study semaglutide in obesity are producing a steady stream of impressive results. Yesterday in the New England Journal of Medicine, a randomized controlled trial in persons with obesity and heart failure with preserved ejection fraction demonstrated superior weight reduction, improvement in heart failure, better physical functioning, and a halving of serious adverse events. […]
February 10, 2021 — High intensity interval training (HIIT) is hot right now. It mixes short periods of very intense exercise with less intense recovery. Even before the pandemic, interest in HIIT had grown dramatically. Then it spiked when pandemic lockdowns began. But a new RCT published yesterday in JAMA suggests that it might not be a panacea for […]
